CLPT
ClearPoint Neuro, Inc.
CLPT offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over CLPT overall, supported by stronger fundamentals and lower modeled downside.
CLPT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
CLPT's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CLPT PE Valuation
CLPT has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CLPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CLPT's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CLPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.20 | -$0.36 |
| Q2 2026 | -$1.17 | -$0.36 |
| Q1 2026 | -$1.00 | -$0.24 |
| Q4 2025 | -$0.90 | -$0.20 |
| Q3 2025 | -$0.84 | -$0.16 |
| Q2 2025 | -$0.81 | -$0.11 |
| Q1 2025 | -$0.76 | +$0.07 |
| Q4 2024 | -$0.70 | +$0.20 |
CLPT lost $1.20 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CLPT on earnings quality, reporting a profit while its opponent remains loss making.
CLPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.1M | +36% |
| Q2 2026 | $10.9M | +18% |
| Q1 2026 | $12.1M | +43% |
| Q4 2025 | $10.4M | +34% |
| Q3 2025 | $8.9M | +9.1% |
| Q2 2025 | $9.2M | +17% |
| Q1 2025 | $8.5M | +11% |
| Q4 2024 | $7.8M | +14% |
CLPT's revenue has grown year over year every quarter since late 2020: $12M last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -52% | +7.1 points |
| Q2 2026 | -94% | -33 points |
| Q1 2026 | -70% | +2.7 points |
| Q4 2025 | -68% | +4.4 points |
| Q3 2025 | -60% | +4.1 points |
| Q2 2025 | -62% | -1.3 points |
| Q1 2025 | -73% | -17 points |
| Q4 2024 | -72% | -3 points |
CLPT's operating margin was −52% last quarter, up 7.1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CLPT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CLPT on profitability, with a higher operating margin.
CLPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.2M | -$16.9M |
| Q2 2026 | -$7.2M | -$4.6M |
| Q1 2026 | -$8.6M | -$2.3M |
| Q4 2025 | -$12.1M | -$10.6M |
| Q3 2025 | -$3.3M | -$2.1M |
| Q2 2025 | -$2.6M | +$25K |
| Q1 2025 | -$6.4M | -$2.5M |
| Q4 2024 | -$1.5M | -$316K |
CLPT has burned cash in almost every quarter: −$48M over the past year, against −$14M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CLPT on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +817K shares |
| 1 year | +9% | +2.6M shares |
| 3 years | +26% | +6.4M shares |
| 5 years | +38% | +8.5M shares |
| Available history | +136% | +17.8M shares |
CLPT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CLPT Net Leverage
CLPT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CLPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 9.1 | Oversold |
CLPT's weekly RSI is 36 (neutral) and its Stochastic is 9 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CLPT PE vs Healthcare Sector
CLPT has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CLPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.3 | 17% below |
| 20 week MA | $13.2 | 36% below |
| 50 week MA | $13.0 | 34% below |
| 100 week MA | $13.8 | 39% below |
| 200 week MA | $10.8 | 22% below |
CLPT is in a downtrend: it's below all five of its weekly moving averages, and 22% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CLPT on trend strength, trading above more of its moving averages.
CLPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.03 | $13.8 | +175% |
| 2021 | $13.8 | $11.8 | -15% |
| 2022 | $11.8 | $7.96 | -32% |
| 2023 | $7.96 | $6.79 | -15% |
| 2024 | $6.79 | $15.8 | +132% |
| 2025 | $15.8 | $14.0 | -11% |
| 2026 YTD | $14.0 | $8.49 | -39% |
CLPT has finished lower in four of the last six years. It's down 39% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CLPT on returns for 2026, with the stronger performance.